RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Cited by (655)

Items 401–500 of 655

1. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
   Yi Ma, Lijie He, Qianwen Huang, Shuang Zheng, Zhiqiang Zhang, Hongshi Li, Shuang Liu · 2018 · BMC Medical Genetics
2. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
   Zhanhong Xie, Yingying Gu, Xinqing Lin, Ming Ouyang, Yinyin Qin, Jiexia Zhang, Junjun Liu, Suiyi Mai, Chengzhi Zhou · 2019 · Cancer Biology & Therapy
3. Notch signaling triggers the tumor heterogeneity of small cell lung cancer
   Lydia Meder, Reinhard Büttner, Margarete Odenthal · 2017 · Journal of Thoracic Disease
4. Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer
   Jing Meng, Xia He, Cheng Zhi Cai, Qi Zhi Ma, Kai Li, Ben Xia Zhang, Yuan Yin, Mingsong Shi, Yong Sheng Wang · 2023 · Biochemical and Biophysical Research Communications
5. Chromatin accessibility landscape of relapsed pediatric B-lineage acute lymphoblastic leukemia
   Han Wang, Huiying Sun, Bilin Liang, Fang Zhang, Fan Yang, Bowen Cui, Lixia Ding, Xiang Wang, Ronghua Wang, Jiaoyang Cai et al. · 2023 · Nature Communications
6. Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection?
   Helmut Popper, Luka Brčić, Sylvia Eidenhammer · 2023 · Translational Lung Cancer Research
7. Liquid biopsy for the management of NSCLC patients under osimertinib treatment
   Aliki Ntzifa, Theodoros Marras, Vassilis Georgoulias, Evi S. Lianidou · 2024 · Critical Reviews in Clinical Laboratory Sciences
8. Transformation to Neuroendocrine Phenotype in Non-Small-Cell Lung Carcinoma: A Literature Review
   Irene Hernández de Córdoba, Xabier Mielgo-Rubio, Paloma Cejas, Jorge Palomar Ramos, Beatriz Garrido-Rubiales, Sandra Falagán Martínez, Gustavo Rubio Romero, María Morales Parga, L. Moll Taltavull, Andrea Fernández González et al. · 2025 · International Journal of Molecular Sciences
9. Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high‐grade neuroendocrine carcinoma
   Jikai Zhao, Jinchen Shao, Ruiying Zhao, Rong Li, Keke Yu, Lei Zhu, Jie Zhang · 2017 · Thoracic Cancer
10. Morphologic and Other Forms of Heterogeneity in Small Cell Lung Cancer: What Can We Learn from Them?
    Adi F. Gazdar · 2018 · Journal of Thoracic Oncology
11. RB1, Cancer Lineage Plasticity, and Therapeutic Resistance
    Letian Zhang, David W. Goodrich · 2022 · Annual Review of Cancer Biology
12. The E3 Ubiquitin Ligase Fbxo4 Functions as a Tumor Suppressor: Its Biological Importance and Therapeutic Perspectives
    Shuo Qie · 2022 · Cancers
13. Combined small cell lung carcinoma and giant cell carcinoma: a case report
    Tomohito Saito, Koji Tsuta, Kento J. Fukumoto, Hiroshi Matsui, Toshifumi Konobu, Yoshitaro Torii, Takashi Yokoi, Takayasu Kurata, Hiroaki Kurokawa, Yoshiko Uemura et al. · 2017 · Surgical Case Reports
14. Brain cancer genomics and epigenomics
    Tenley C. Archer, Soma Sengupta, Scott L. Pomeroy · 2018 · Handbook of clinical neurology
15. Neuroendocrine Transformation as a Mechanism of Resistance to Targeted Lung Cancer Therapies: Emerging Mechanisms and Their Therapeutic Implications
    Asim Joshi, Nivitha Bhaskar, Joel D. Pearson · 2025 · Cancers
16. Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer
    Giulia La Cava, Alessio Cortellini, Julia K. Rotow, Jessica Ruth Bauman · 2025 · American Society of Clinical Oncology Educational Book
17. Prevalence of Histological Transformation in First-Line Osimertinib Non-Small Cell Lung Cancers: Case Series and Literature Review
    Rebecca Sparavelli, Rossella Bruno, Alessandra Celi, Andrea Sbrana, Iacopo Petrini, Antonio Chella, Clara Ugolini, Greta Alì · 2025 · International Journal of Molecular Sciences
18. Transformational Changes Between Non–Small Cell and Small Cell Lung Cancer—Biological and Clinical Relevance—A Review
    Gerald H. Clamon, William Andrew Zeitler, Josiah An, Taher Abu Hejleh · 2020 · American Journal of Clinical Oncology
19. A clinical decision support system to predict the efficacy for EGFR-TKIs based on artificial neural network
    Liang Xiao, Runwei Guan, Jiamin Zhu, Yue Meng, Jing Zhu, Yuxiang Yang, Yanan Cui, Jiali Dai, Weidong Mao, Liting Lv et al. · 2023 · Journal of Cancer Research and Clinical Oncology
20. AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting
    Elaine C. Maggi, Cristina Montagna · 2015 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
21. Notch signaling and Tp53/RB1 pathway in pulmonary neuroendocrine tumorigenesis
    Takaaki Ito, Akira Matsuo, Wael Abdo Hassan · 2016 · Translational Cancer Research
22. Significance of genetic sequencing in patients with lung adenocarcinoma with transformation to small cell lung cancer: a case report and systematic review
    Cuicui Zhang, Lin Li, Xin Guo, Peng Chen · 2020 · Translational Cancer Research
23. In‐depth molecular analysis of combined and co‐primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma
    B.C.M. Hermans, Jules L. Derks, Lisa Maria Hillen, Irene van der Baan, Esther C. van den Broek, Jan H. von der Thüsen, Robert Jan van Suylen, Peggy N. Atmodimedjo, T. Dorine den Toom, Cecile M. Stallinga et al. · 2021 · International Journal of Cancer
24. Studying Lineage Plasticity One Cell at a Time
    Benjamin Jacob Drapkin, John Dorrance Minna · 2020 · Cancer Cell
25. An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report
    Shinichi Miyazaki, Yasumasa Kuno, Shunsaku Hayai, Ryo Teramachi, Ryo Yamashita, Yusuke Saito, Kosuke Higuchi, Yoshiharu Nara, Takuya Ikeda · 2020 · Journal of Medical Case Reports
26. Treatment of lung cancer by acupuncture combined with medicine based on pathophysiological mechanism: A review
    Chenguang Guan, Huiwan Chen, Haipeng Chen, Shuhua Li, Yuhan Chen, Jingyu Chen, Yushan Dong, Zhitao Zheng, Kaiwen Wang, Chuqiao Pan · 2024 · Medicine
27. Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene
    Marcin Nicoś, Anna Sroka‐Bartnicka, Ewa Kalinka‐Warzocha, Paweł Adam Krawczyk · 2025 · Cancers
28. Molecular mechanisms and therapeutic strategies for small‑cell lung cancer transformation after TKI therapy in EGFR‑mutated lung adenocarcinoma (Review)
    Hongbing Zhang, Hongye Gao, Penghu Gao, Hongyu Liu, Jun Chen · 2025 · Molecular and Clinical Oncology
29. Transcriptomic analysis of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals distinct subgroups and precision therapy opportunities
    Hao Sun, Chan-Yuan Zhang, Xiu-Hao Zhang, Zaixian Tai, Junwei Su, Xiao-Cheng Lin, Shiling Zhang, Yufa Li, Chao Zhang, Miao Cai et al. · 2025 · Biomarker Research
30. Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition
    Adam Rock, Isa Mambetsariev, Siddhika Pareek, Jeremy Fricke, Xiaochen Li, Javier Arias-Romero, Waasil Kareem, Leonidas D. Arvanitis, Débora S. Bruno, Stacy W. Gray et al. · 2025 · Current Oncology
31. An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update
    Luigi Cerbone, José Carlos Benítez, David Planchard, Carlo Genova · 2021 · Expert Opinion on Pharmacotherapy
32. Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver
    Matthew G. Oser, Pasi Antero Janne · 2018 · Clinical Cancer Research
33. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma
    Shivangi Awasthi, Tapan Kumar Maity, Benjamin L. Oyler, Yue Andy Qi, Xu Zhang, David R. Goodlett, Udayan Guha · 2018 · Journal of Proteomics
34. Trilaciclib: A First-in-class Therapy to Reduce Chemotherapy-induced Myelosuppression
    Joanna Alyse Young, Antoinette R. Tan · 2022 · touchREVIEWS in Oncology & Haematology
35. PRMT5 promotes chemotherapy‐induced neuroendocrine differentiation in NSCLC
    Qi Shen, Yi Liu, Xuehong Deng, Chang‐Deng Hu · 2023 · Thoracic Cancer
36. Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas
    Ibiayi Dagogo‐Jack, Andreas Nicholas Saltos, Alice Tsang Shaw, Jhanelle E. Gray · 2017 · American Society of Clinical Oncology Educational Book
37. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
    Ahsan Wahab, Kavitha Kesari, Siddique Chaudhary, Mahin R. Khan, Hafiz Muhammad Waqas Khan, Susan Smith, Yanis Boumber · 2017 · Cancer Biology & Therapy
38. Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report
    Naoya Nishioka, Tadaaki Yamada, Sachi Harita, Soichi Hirai, Yuki Katayama, Takayuki Nakano, Naoko Okura, Nobuyo Tamiya, Yoshiko Kaneko, Junji Uchino et al. · 2018 · Respiratory Medicine Case Reports
39. The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers
    Helmut Popper, Ulrike Gruber-Moesenbacher, Georg Pall, Leonhard Müllauer, Maximilian Johannes Hochmair, Dagmar Krenbek, Luka Brčić, Katja Schmitz, Bernd Lamprecht, Josef Eckmayr et al. · 2020 · memo - Magazine of European Medical Oncology
40. Griffin: Framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
    Anna-Lisa Doebley, Minjeong Ko, Hanna Liao, A. Eden Cruikshank, Caroline Kikawa, Katheryn Santos, Joseph B. Hiatt, Robert D. Patton, Navonil De Sarkar, Anna C. H. Hoge et al. · 2021 · medRxiv
41. Transformation of lung adenocarcinoma to small cell lung cancer following osimertinib treatment: a case report and literature review
    Linwu Kuang, Peng Wang, Lin Zhou, Yangkai Li · 2025 · Anti-Cancer Drugs
42. The emerging landscape and future perspective of SCLC transformation: From molecular mechanisms to therapeutic strategies
    Chenyue Zhang, Kai Wang, Haiyong Wang · 2025 · Critical Reviews in Oncology/Hematology
43. Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non‐Small Cell Lung Cancers
    Jinjing Tan, Dan Zhao, Qunhui Wang, Yanjing Peng, Jie Li, Xi Li, Nanying Che, Ying Hu, Hua Zheng · 2025 · Cancer Medicine
44. Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report
    Qinghan Liu, Lin Wu, Suning Zhang · 2020 · Tumori Journal
45. [Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma].
    Shuping Xue, Tingting Yu, Yan Zhang, Shan Li · 2015 · Europe PMC (PubMed Central)
46. Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma
    Misaki Iijima, Takehiko Yokobori, Akira Mogi, Kimihiro Shimizu, Toshiki Yajima, Takayuki Kosaka, Yoichi Ohtaki, Kai Obayashi, Seshiru Nakazawa, Navchaa Gombodorj et al. · 2019 · Annals of Surgical Oncology
47. Crizotinib Resensitization by Compound Mutation
    Paola Bordi, Marzia Del Re, Marcello Tiseo · 2016 · New England Journal of Medicine
48. TP53 mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance
    Martin Michaelis, Constanze Schneider, Florian Rothweiler, Tamara Rothenburger, Marco Mernberger, Andrea Nist, Andreas von Deimling, Daniel Speidel, Thorsten Stiewe, Jindrich Jr. Cinatl · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
49. Genomic and transcriptomic profiling of combined small-cell lung cancer through microdissection: unveiling the transformational pathway of mixed subtype
    Wenjuan Ma, Ting Zhou, Mengmeng Song, Jiaqing Liu, Gang Chen, Jianhua Zhan, Liyan Ji, Fan Luo, Xuan Gao, Pansong Li et al. · 2024 · Journal of Translational Medicine
50. Histologic transformation after targeted therapy resistance in driver gene-positive NSCLC: mechanisms and therapeutic challenges
    Xinyue Li, Kaibo Ding, Dujiang Liu, Yuxia Wang, Yanjun Xu · 2025 · Therapeutic Advances in Medical Oncology
51. Histologic Transformation in Cancer: The Path for Clinical Translation
    Ioannis Athanasios Vathiotis, Avisek Banerjee, Utsav Sen, Felix Carl Saalfeld, Debdatta Halder, Andriani G. Charpidou, Konstantinos N. Syrigos, Hidehito Horinouchi, Ashutosh Kumar Tewari, Mark A. Dawson et al. · 2025 · Cancer Discovery
52. The SWI/SNF complex member SMARCB1 supports lineage fidelity in kidney cancer
    Ludovic Wesolowski, Jianfeng Ge, Leticia Castillon, Debora Sesia, Anna Dyas, Shoko Hirosue, Veronica Caraffini, Anne Yvonne Warren, Paulo Rodrigues, Giovanni Ciriello et al. · 2023 · iScience
53. Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
    Krešimir Tomić, Kristina Krpina, Lara Batičić, Miroslav Samaržija, Semir Vranić · 2024 · Journal of drug targeting
54. Design, synthesis and antitumour activity of pyrimidine derivatives as novel selective EGFR kinase inhibitors
    Cheng Zhang, Yiwen Huo, Jianfang Fu, Yue Liu, Qinjiang Zhou, Mingyue Hou, Xiaoxuan Duan, Yanna Lv, Jinxing Hu · 2025 · Molecular Diversity
55. Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report
    Guotao Fang, Weiwei Liu, Yanhong Shang, Ran Huo, Xiaoliang Shi, Yanan Wang, Jinghua Li · 2022 · Annals of Translational Medicine
56. Spontaneous histological transformation of lung squamous-cell carcinoma to large cell neuroendocrine carcinoma and small cell lung cancer
    Jindong Li, Cheng-Yan Jin, Yan Zhang, Hang Guo, Guang-Lei Zhang, Chun-Guang Wang · 2023 · Journal of Cancer Research and Clinical Oncology
57. Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC
    Isabelle Vanden Bempt, Els Wauters, Johan Vansteenkiste · 2018 · Annals of Oncology
58. Drug Resistance and Its Clinical Circumvention
    Jeffrey A. Moscow, Shannon K. Hughes, Kenneth H. Cowan, Branimir Ivan Sikic · 2022 · Holland‐Frei Cancer Medicine
59. EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
    Atsuko Ogino, Amir Vajdi, Xinmeng Jasmine Mu, Navin R. Mahadevan, Kenneth H. Ngo, Matthew Aaron Booker, Paloma Cejas, Jeffrey J. Okoro, Man Xu, Benjamin F. Springer et al. · 2026 · JCI Insight
60. Diverse and reprogrammable mechanisms of malignant cell transformation in lymphocytes: pathogenetic insights and translational implications
    Mariusz A. Wasik, Patricia M. Kim, Reza Nejati · 2024 · Frontiers in Oncology
61. Selinexor as a Therapeutic Target: Advances in Non-small Cell and Small Cell Lung Cancer Treatment Strategies
    Bosheng Zheng, Wenqi Zhang, Shaonan Xie, Yaqing Han, Guangjie Liu, Yanjie Liu, Maogang Gao, Shize Wang, Qingyi Liu · 2024 · Recent Patents on Anti-Cancer Drug Discovery
62. Transformation of lung adenocarcinoma into small cell lung cancer after treatment with epidermal growth factor receptor tyrosine kinase inhibitors
    Linwu Kuang, Yangkai Li · 2024 · Oncology and Translational Medicine
63. Epigenomic analysis identifies DTP subpopulation using HOPX to develop targeted therapy resistance in lung adenocarcinoma
    Yang Tian, Reshmee Bhattacharya, Seungyeul Yoo, Feng Jiang, Eric Y. H. Park, Genesis Lara Granados, Yudao Shen, Kwang‐Su Park, H. Ümit Kanıskan, Jian Jun Jin et al. · 2025 · iScience
64. Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations
    Jingrui Jiang, Alexei I. Protopopov, Ruobai Sun, Stephen R. Lyle, Meaghan K. Russell · 2018 · Journal of Personalized Medicine
65. Small Cell Lung Cancer in Light/Never Smokers – A Role for Molecular Testing?
    Gordon Taylor Moffat, Tao Wang, Andrew George Robinson · 2023 · Journal of the National Comprehensive Cancer Network
66. Bruceine D and afatinib combination inhibits ovarian cancer cells proliferation and migration through DNA damage repair and EGFR pathway
    Jufan Zhu, Luo Wang, Yuanjun Yang, Mengfei Han, Yiheng Yang, Renqian Feng, Yan Hu · 2023 · Journal of Investigative Medicine
67. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors
    William Shaffer, Ikei S. Kobayashi, Daniel Sentana‐Lledo, Shriram K. Sundararaman, Meghan D. Lee, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel Botelho Costa · 2023 · Lung Cancer
68. Evasion of targeted cancer therapy through stem-cell-like reprogramming
    Kristine M. Wadosky, Leigh Ellis, David W. Goodrich · 2017 · Molecular & Cellular Oncology
69. Pulmonary Adenocarcinoma—Pathology and Molecular Testing
    Prodipto Pal, Michael Cabanero, Ming‐Sound Tsao · 2018 · Elsevier eBooks
70. Successful treatment with temozolomide in an elderly woman with advanced pulmonary large-cell neuroendocrine carcinoma
    Juan Wei, Xiao Fang Dong, Zu Liang Hu, Sheng Tang, Yi Fang Lu · 2018 · Medicine
71. The genomic imprint of cancer therapies helps timing the formation of metastases
    Eszter Németh, Marcin Krzystanek, Lilla Reiniger, Dezső Ribli, Orsolya Pipek, Zsófia M. Sztupinszki, Tibor Glasz, István Csabai, Judit Moldvay, Zoltán Szállási et al. · 2019 · International Journal of Cancer
72. Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma
    Hao-Ran Zhai, David A. Moore, Mariam Jamal‐Hanjani · 2020 · Annals of Oncology
73. CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer
    Beatrice Gini, Philippe Gui, Wei Wu, Daniel Lucas Kerr, Lisa Tan, Dora Barbosa, Victor R. Olivas, Paul Allegakoen, Carlos Gomez, Patrick R. Halliday et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
74. An identity crisis for lung cancer cells
    Àlvaro Quintanal-Villalonga · 2024 · Science Translational Medicine
75. RB1 and p53 are diagnostic markers for treatment-related neuroendocrine prostate cancer: a clinical and pathological analysis of 23 cases
    Yutao Zhang · 2025 · American Journal of Clinical and Experimental Urology
76. Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies
    Montse Sanchez-Cespedes, William W. Lockwood, Kenichi Suda, Eric E. Gardner, Tetsuya Mitsudomi, Katerina Politi, Christian Rolfo, Triparna Sen, Martin L. Sos, Tuomas Tammela et al. · 2025 · JTO Clinical and Research Reports
77. Molecular Landscape of TP53 / RB1 Co‐Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities
    X. Li, Meifeng Ye, Xiaomei Huang, Zhong‐Yin Huang, Juan Zhu, Zipeng He, Zhuxiang Zhao, Jun Hou, Shuquan Wei · 2026 · Genes Chromosomes and Cancer
78. Clinicogenomic analysis of EGFR -mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation
    Alexandria Dymun, Mark Yungjie Jeng, Arielle Elkrief, Harshita Mehrotra, Soo‐Ryum Yang, Christina E. Wilson, Natasha Rekhtman, Irina Linkov, Amanda Pupo, Christina J. Falcon et al. · 2026 · Science Translational Medicine
79. Non–Small Cell Lung Cancer to Small Cell Lung Cancer Transformation: A Clinical Challenge
    Kostas A. Papavassiliou, Amalia A. Sofianidi, Vassiliki A. Gogou, Georgios Marinos, Athanasios G. Papavassiliou · 2025 · American Journal of Respiratory and Critical Care Medicine
80. Baseline retinoblastoma transcriptional corepressor 1 (Rb1) functional inactivation is a pre-requisite but not sufficient for small-cell histological transformation in epidermal growth factor receptor (EGFR) mutant lung adenocarcinomas post-tyrosine kinase inhibitor therapy
    Aruna Nambirajan, Amber Rathor, Hemavathi Baskarane, Anju GS, Sachin Khurana, Somagattu Sushmitha, Aparna Sharma, Prabhat Singh Malik, Deepali Jain · 2025 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
81. Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first‑generation EGFR‑TKIs in a real‑world clinical setting
    Tongtong Hou, Jiahao Zeng, Hanyan Xu, Shanshan Su, Junru Ye, Yuping Li · 2022 · Molecular and Clinical Oncology
82. Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets
    Ugo Testa, Elvira Pelosi, Germana Castelli · 2022 · Onco
83. Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach
    Elisa Baldelli, Martina Mandarano, Guido Bellezza, Emanuel F. Petricoin, Mariaelena Pierobon · 2022 · Cell Reports Methods
84. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review
    Yefan Zhang, Zhen Huang · 2023 · Frontiers in Pharmacology
85. A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition
    Daniel S. Lenchner, Zaritza O. Petrova, Lisa W. Hunihan, Kumar Dilip Ashtekar, Zenta Walther, Frederick Hugh Wilson · 2024 · npj Precision Oncology
86. [Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer].
    Zitong Zhao, Yu Ni, Li Li, Tao Xin · 2020 · PubMed Central
87. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy
    Yiyu Lu, Zhihua Li, Huawei Zhu, Juan Zhao, Mian Xu, Weiguang Gu · 2021 · Annals of Palliative Medicine
88. De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
    Takanori Ito, Issei Oi, Zentaro Saito, Takuma Imakita, Osamu Kanai, Kohei Fujita, Hiromasa Tachibana, Koki Moriyoshi, Tadashi Mio · 2023 · JTO Clinical and Research Reports
89. Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study
    Junwei Huang, Xianxu Zhang, Yue Cai, Dong Yang, Jian Shi, Puyuan Xing, Tun Xu, Lianguo Wu, Wenmei Su, Rui‐Hua Xu et al. · 2023 · Clinical Oncology
90. ALK-rearranged and EGFR wild-type lung adenocarcinoma transformed to small cell lung cancer: a case report
    Rui Chen, Yan Jian, Yuzhen Liu, Junping Xie · 2024 · Frontiers in Oncology
91. Small Cell Cancer Transformation of Lung Adenocarcinoma During Durvalumab Treatment After Chemoradiotherapy
    Sayaka Arakawa, Tatsuya Yoshida, Yuko Nakayama, Noriko Motoi, Yuichiro Ohe · 2020 · Journal of Thoracic Oncology
92. Adenocarcinoma transformed into squamous cell carcinoma in non-small cell lung cancer
    Yueqiang Jiang, Jun Zhang, Jin Feng, Ya-Ping Lü, Yuan Fan, Ling Cheng, Xin Liao, Liya Hu, Shiying Yu, Tiejun Yin · 2021 · Journal of genetics and genomics/Journal of Genetics and Genomics
93. Extracellular matrix regulates lineage plasticity in prostate cancer through YAP/TEAD
    Teng Han, Zhen Sun, Matthew Lange, Y Zoe Cho, Patrick D. McGillivray, Maren Büttner, Nathaniel R. Kastan, Subhiksha Nandakumar, HuiYong Zhao, Eralda Salataj et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
94. Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors
    Hannah M Hylton-McComas, Anna F. Cordes, Konstantinos V. Floros, Anthony C. Faber, Benjamin Jacob Drapkin, Wayne O. Miles · 2025 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
95. Subtype-specific dependencies and therapeutic opportunities in small cell lung cancer
    Amanda Luvisotto, Rima Tulaiha, Lu Wang · 2026 · Science Advances
96. Small-Cell Carcinoma of the Prostate – Challenges of Diagnosis and Treatment: A Next of Kin and Physician Perspective Piece
    Trish Abbott, Kenrick Ng, Jenny Penelope Nobes, Paula Muehlschlegel · 2023 · Oncology and Therapy
97. Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report
    Jun Nishimura, Yosuke Miyamoto, Nobukazu Fujimoto, Taichi Ozeki, Kenji Takada, Michiko Asano, Yasuko Fuchimoto, Sae Wada, Shinji Ozaki, Takumi Kishimoto · 2017 · Case Reports in Oncology
98. Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report
    Er Hong, Xi-Er Chen, Jia Mao, Jingjing Zhou, Ling Chen, Jia-Yi Xu, Wei Tao · 2022 · World Journal of Clinical Cases
99. A Review on Small-Cell Lung Cancer: Epidemiology, Pathophysiology, Risk Factors, Diagnosis, Clinical Management and Treatment Modalities
    Md Shamshir Alam · 2023 · International Journal of Current Science Research and Review
100. Tumor grade-associated genomic mutations in Chinese patients with non-small cell lung cancer
     Yang Wang, Shilei Qin, Yuepei Liang, Ling Yan, Min Zheng, Yanwu Zeng, Leilei Lu · 2023 · Frontiers in Oncology